

Fabrice Andre

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/380802/fabrice-andre-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

443
papers

46,402
citations

103
h-index

209
g-index

525
ext. papers

57,264
ext. citations

8.4
avg, IF

7.36
L-index

#	Paper	IF	Citations
443	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.. <i>Npj Breast Cancer</i> , 2022 , 8, 3	7.8	4
442	Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101252	2.2	5
441	Uptake of Recommendations for Posttreatment Cancer-Related Fatigue Among Breast Cancer Survivors.. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022 , 1-13	7.3	0
440	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe.. <i>Journal of Personalized Medicine</i> , 2022 , 12,	3.6	5
439	Immunotherapy for early triple negative breast cancer: research agenda for the next decade.. <i>Npj Breast Cancer</i> , 2022 , 8, 23	7.8	7
438	Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer. <i>Cancer Research</i> , 2022 , 82, GS2-01-GS2-01	10.1	0
437	Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY). <i>Cancer Research</i> , 2022 , 82, PD8-02-PD8-02	10.1	6
436	The polarity and specificity of antiviral T lymphocyte responses determine susceptibility to SARS-CoV-2 infection in cancer patients and healthy individuals.. <i>Cancer Discovery</i> , 2022 ,	24.4	2
435	Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. <i>Cancer Research</i> , 2022 , 82, PD2-05-PD2-05	10.1	0
434	Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.. <i>BMJ Open</i> , 2022 , 12, e055821	3	4
433	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 942-950	59.2	18
432	Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101958	2.2	2
431	Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.. <i>Cancer Treatment Reviews</i> , 2022 , 106, 102378	14.4	4
430	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102767	2.2	7
429	Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France.. <i>JAMA Network Open</i> , 2022 , 5, e225118	10.4	0
428	Delivering precision oncology to patients with cancer.. <i>Nature Medicine</i> , 2022 , 28, 658-665	50.5	7
427	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200069	2.2	15

426	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2100277	2.2	1
425	Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients. <i>EBioMedicine</i> , 2022 , 80, 104077	8.8	2
424	Immunodynamics of explanted human tumors for immuno-oncology. <i>EMBO Molecular Medicine</i> , 2021 , 13, e12850	12	2
423	Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss of Heterozygosity Score. <i>Clinical Cancer Research</i> , 2021 ,	12.9	9
422	Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. <i>European Journal of Cancer</i> , 2021 , 159, 283-295	7.5	1
421	Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. <i>JAMA Oncology</i> , 2021 ,	13.4	9
420	A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). <i>European Journal of Cancer</i> , 2021 , 158, 169-180	7.5	2
419	Genomic Alterations in -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3K β Inhibitors. <i>Cancer Research</i> , 2021 , 81, 2470-2480	10.1	6
418	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. <i>Cell Death and Disease</i> , 2021 , 12, 258	9.8	37
417	Tribbles Pseudokinase 3 Regulation and Contribution to Cancer. <i>Cancers</i> , 2021 , 13,	6.6	4
416	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 499-511	21.7	68
415	Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvements. <i>Cancer</i> , 2021 , 127, 2774-2787	6.4	2
414	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. <i>Cancer Discovery</i> , 2021 , 11, 874-899	24.4	26
413	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. <i>Genome Medicine</i> , 2021 , 13, 87	14.4	8
412	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. <i>Cell Death and Differentiation</i> , 2021 , 28, 2778-2796	12.7	13
411	Multifaceted modes of action of the anticancer probiotic <i>Enterococcus hirae</i> . <i>Cell Death and Differentiation</i> , 2021 , 28, 2276-2295	12.7	9
410	PI3K inhibitors are finally coming of age. <i>Nature Reviews Drug Discovery</i> , 2021 , 20, 741-769	64.1	45
409	Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. <i>Breast</i> , 2021 , 57, 43-48	3.6	1

408	Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index. <i>Cell Death and Disease</i> , 2021 , 12, 599	9.8	5
407	Patient-Reported Outcomes in Patients With -Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2005-2015	2.2	7
406	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021 , 28, 3297-3315	12.7	7
405	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 309-317	9.7	19
404	Differentiation of groups of patients with cognitive complaints at breast cancer diagnosis: Results from a sub-study of the French CANTO cohort. <i>Psycho-Oncology</i> , 2021 , 30, 463-470	3.9	0
403	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021 , 11, 408-423	24.4	12
402	AI-driven quantification, staging and outcome prediction of COVID-19 pneumonia. <i>Medical Image Analysis</i> , 2021 , 67, 101860	15.4	53
401	Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. <i>Annals of Oncology</i> , 2021 , 32, 208-217	10.3	70
400	ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. <i>Annals of Oncology</i> , 2021 , 32, 337-350	10.3	24
399	Alpelisib in combination with everolimus + exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. <i>European Journal of Cancer</i> , 2021 , 151, 49-62	7.5	5
398	Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue. <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 517-529	4.4	1
397	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021 , 32, 1216-1235	10.3	44
396	Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. <i>Nature Medicine</i> , 2021 , 27, 250-255	50.5	28
395	Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. <i>Annals of Oncology</i> , 2020 , 31, 1001-1010	10.3	38
394	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020 , 6, 15	7.8	8
393	Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020 , 132, 211-223	7.5	23
392	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 17	7.8	54
391	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2762-2772	2.2	39

390	Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100023	1.4	4
389	The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers. <i>Cancer Research</i> , 2020 , 80, 3062-3069	10.1	2
388	Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing. <i>Cancer Research</i> , 2020 , 80, 2190-2203	10.1	4
387	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. <i>Lancet, The</i> , 2020 , 395, 817-827	40	116
386	Cognitive Impairment in Patients with Breast Cancer before Surgery: Results from a CANTO Cohort Subgroup. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1759-1766	4	3
385	Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. <i>Annals of Oncology</i> , 2020 , 31, 377-386	10.3	61
384	Characteristics and Outcome of -Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. <i>Cancer Discovery</i> , 2020 , 10, 526-535	24.4	19
383	A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19-positive patients with cancer. <i>European Journal of Cancer</i> , 2020 , 132, 1-4	7.5	13
382	HER2-Low Breast Cancer: Pathological and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1951-1962	2.2	74
381	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchER): a randomised, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 763-775	21.7	69
380	Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study. <i>Breast</i> , 2020 , 52, 23-32	3.6	8
379	Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments 2020 ,		19
378	Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01) 2020 ,		3
377	Abstract GS3-02: Durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: Results from phase II randomized trial SAFIR02-IMMUNO 2020 ,		9
376	Abstract P4-10-04: Clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: Biomarker analysis from the SOLAR-1 study 2020 ,		2
375	Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) 2020 ,		19
374	Genomic Alteration in Metastatic Breast Cancer and Its Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 1-14	7.1	71
373	Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1009-1009	2.2	12

372	Self-supervised Nuclei Segmentation in Histopathological Images Using Attention. <i>Lecture Notes in Computer Science</i> , 2020 , 393-402	0.9	12
371	Ribosomal RNA 2'O-methylation as a novel layer of inter-tumour heterogeneity in breast cancer. <i>NAR Cancer</i> , 2020 , 2, zcaa036	5.2	12
370	Reply to A. Katz. <i>Journal of Clinical Oncology</i> , 2020 , 38, 102-103	2.2	
369	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 242-255	12.9	55
368	Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO). <i>Journal of Clinical Oncology</i> , 2020 , 38, 734-743	2.2	31
367	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 610-621	59.2	536
366	Prediction of Breast Cancer Treatment-Induced Fatigue by Machine Learning Using Genome-Wide Association Data. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa039	4.6	1
365	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020 , 31, 1623-1649	10.3	282
364	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020 , 31, 1491-1505	10.3	223
363	Progresses Toward Precision Medicine in -altered Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 6102-6111	6.1	13
362	Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation. <i>Cell Reports</i> , 2020 , 33, 108421	10.6	19
361	Body weight and return to work among survivors of early-stage breast cancer. <i>ESMO Open</i> , 2020 , 5, e000908	0.9	6
360	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020 , 11, 3819	17.4	41
359	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. <i>Cell</i> , 2020 , 182, 1401-1418.e18	56.2	359
358	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , 2020 , 587, 126-132	50.4	67
357	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort.. <i>Nature Cancer</i> , 2020 , 1, 965-975	15.4	58
356	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. <i>Npj Precision Oncology</i> , 2020 , 4, 27	9.8	3
355	Immune responses during COVID-19 infection. <i>OncImmunity</i> , 2020 , 9, 1807836	7.2	49

354	Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. <i>Science</i> , 2020 , 369, 936-942	33.3	74
353	Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 387-401	4.4	5
352	Lucitanib for the Treatment of HR/HER2 Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020 , 26, 354-363	12.9	19
351	TROPICS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. <i>Future Oncology</i> , 2020 , 16, 705-715	3.6	23
350	Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. <i>Clinical Chemistry</i> , 2019 , 65, 1405-1413	5.5	31
349	Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). <i>Annals of Oncology</i> , 2019 , 30, 365-373	10.3	55
348	A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 743-753	3.5	11
347	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1956-1964	2.2	113
346	6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. <i>Lancet, The</i> , 2019 , 393, 2591-2598	40	52
345	Genomic characterization of metastatic breast cancers. <i>Nature</i> , 2019 , 569, 560-564	50.4	256
344	Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 1929-1940	59.2	853
343	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2019 , 15, 1951-1961	3.6	33
342	ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. <i>Annals of Oncology</i> , 2019 , 30, 1232-1243	10.3	256
341	Fatigue and physical activity in cancer survivors: A cross-sectional population-based study. <i>Cancer Medicine</i> , 2019 , 8, 2535-2544	4.8	13
340	T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants. <i>Annals of Oncology</i> , 2019 , 30, 934-944	10.3	8
339	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019 , 37, 559-569	2.2	282
338	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1169-1178	2.2	127
337	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 371-382	21.7	200

336	Alpelisib for PIK3CA-Mutated Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 686-692	5
335	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2019 , 15, 495-497	3.1 8
334	ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. <i>Annals of Oncology</i> , 2019 , 30, 1417-1427	10.3 133
333	Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. <i>Annals of Oncology</i> , 2019 , 30, 1784-1795	10.3 57
332	Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 23691-23697	11.5 18
331	Abstract CT142: Prevalence of PIK3CA mutations in patients with hormone receptor-positive, human epidermal growth factor-2-negative advanced breast cancer from the SOLAR-1 trial 2019 ,	5
330	RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1092-1092	2.2 11
329	Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 512-512	2.2 1
328	Cognitive impairment in breast cancer patients before surgery?: Results of a subgroup of the French CANTO cohort.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 561-561	2.2 2
327	KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS604-TPS604	2.2 4
326	Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS3159-TPS3159	2.2
325	UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). <i>ESMO Open</i> , 2019 , 4, e000562	6 26
324	Efficacy of PI3K inhibitors in advanced breast cancer. <i>Annals of Oncology</i> , 2019 , 30, x12-x20	10.3 78
323	Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. <i>PLoS Medicine</i> , 2019 , 16, e1002989	11.6 23
322	Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. <i>Annals of Oncology</i> , 2019 , 30, 1941-1949	10.3 78
321	An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. <i>Nature Communications</i> , 2019 , 10, 5713	17.4 28
320	Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline Mutations. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6 4
319	Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis. <i>Breast Cancer Research and Treatment</i> , 2019 , 173, 573-583	4.4 11

318	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. <i>European Journal of Cancer</i> , 2018 , 92, 1-10	7.5	11
317	Funding sources of practice-changing trials. <i>Annals of Oncology</i> , 2018 , 29, 1063-1065	10.3	5
316	Annals of Oncology: factors for making a real impact. <i>Annals of Oncology</i> , 2018 , 29, 28-29	10.3	1
315	Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2018 , 29, 640-645	10.3	162
314	Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. <i>Annals of Oncology</i> , 2018 , 29, 281-282	10.3	2
313	The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. <i>Annals of Oncology</i> , 2018 , 29, 30-35	10.3	57
312	ER Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. <i>Clinical Cancer Research</i> , 2018 , 24, 2517-2529	12.9	19
311	A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. <i>Annals of Oncology</i> , 2018 , 29, 162-169	10.3	26
310	4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) <i>Annals of Oncology</i> , 2018 , 29, 1634-1657	10.3	645
309	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). <i>Annals of Oncology</i> , 2018 , 29, 1895-1902	10.3	181
308	Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. <i>Cancer Journal (Sudbury, Mass)</i> , 2018 , 24, 153-162	2.2	11
307	Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. <i>Annals of Oncology</i> , 2018 , 29, 1755-1762	10.3	23
306	Abstract CT039: Cyclin E1 (CCNE1) expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial 2018 ,		15
305	IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) + atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS1115-TPS1115	2.2	1
304	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018 , 9, 9741-9750	3.3	7
303	Regulation of RNA polymerase III transcription during transformation of human IMR90 fibroblasts with defined genetic elements. <i>Cell Cycle</i> , 2018 , 17, 605-615	4.7	15
302	American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-14	5.2	13
301	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 1926-1936	59.2	478

300	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. <i>Cancer Discovery</i> , 2018 , 8, 1390-1403	24.4	231
299	Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1457-1467	2.2	268
298	Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy. <i>Breast Cancer Research</i> , 2017 , 19, 18	8.3	67
297	Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape. <i>Annals of Oncology</i> , 2017 , 28, 1145-1151	10.3	12
296	3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). <i>Annals of Oncology</i> , 2017 , 28, 16-33	10.3	241
295	AACR Project GENIE: Powering Precision Medicine through an International Consortium. <i>Cancer Discovery</i> , 2017 , 7, 818-831	24.4	629
294	A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2017 , 23, 5366-5373	12.9	89
293	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. <i>Cancer Discovery</i> , 2017 , 7, 586-595	24.4	347
292	Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. <i>Lancet, The</i> , 2017 , 389, 2403-2414	40	112
291	3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). <i>Breast</i> , 2017 , 31, 244-259	3.6	137
290	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. <i>European Journal of Cancer</i> , 2017 , 86, 257-265	7.5	21
289	Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. <i>PLoS ONE</i> , 2017 , 12, e0188174	3.7	65
288	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017 , 28, 1700-1712	10.3	586
287	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2838-2847	2.2	178
286	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Myeloid Leukemia, Endometrial and Ovarian Carcinomas, Sarcoma, and Gliomas of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2838-2847	5.1	299
285	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017 , 24, 235	5.1	293
284	Targeting TCTP with Sertraline and Thioridazine in Cancer Treatment. <i>Results and Problems in Cell Differentiation</i> , 2017 , 64, 283-290	1.4	13
283	Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. <i>Oncologist</i> , 2017 , 22, 1028-1038	5.7	83

282	Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. <i>Annals of Oncology</i> , 2017 , 28, 103-109	10.3	40
281	Abstract 1008: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer 2017 ,		9
280	Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers 2017 ,		9
279	Fatigue and health behaviors in cancer survivors: A cross-sectional population based study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10069-10069	2.2	1
278	A phase II randomized study to compare abemaciclib plus trastuzumab with or without fulvestrant to standard of care chemotherapy plus trastuzumab in hormone receptor positive, HER2-positive advanced breast cancer (monarchHER).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS1109-TPS1109	2.2	3
277	A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS1111-TPS1111	2.2	6
276	An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS1117-TPS1117	2.2	7
275	UNICANCER: Prospective cohort study of treatment related chronic toxicities in patients with localized breast cancer (CANTO).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS10125-TPS10125	2.2	
274	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 575-575	2.2	1
273	The ratio of CD8/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma. <i>Oncolmunology</i> , 2016 , 5, e1218106	7.2	39
272	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations. <i>Cancer Research</i> , 2016 , 76, 5954-5961	10.1	12
271	Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2961-8	2.2	420
270	Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. <i>Annals of Oncology</i> , 2016 , 27, 1047-1054	10.3	94
269	Les essais cliniques : leur apport dans le parcours de soins des patientes traitées pour un cancer du sein. <i>Oncologie</i> , 2016 , 18, 103-108	1	1
268	Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. <i>Clinical Cancer Research</i> , 2016 , 22, 2960-8	12.9	86
267	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. <i>Autophagy</i> , 2016 , 12, 864-75	10.2	75
266	rCGH: a comprehensive array-based genomic profile platform for precision medicine. <i>Bioinformatics</i> , 2016 , 32, 1402-4	7.2	12
265	Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01). <i>European Journal of Cancer</i> , 2016 , 59, 79-89	7.5	27

264	Statistical controversies in clinical research: statistical significance-too much of a good thing □ <i>Annals of Oncology</i> , 2016 , 27, 760-2	10.3	5
263	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1134-50	2.2	543
262	Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance. <i>Cell Cycle</i> , 2016 , 15, 295-302	4.7	18
261	Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e21-3	8.9	7
260	Whole exome sequencing of rare aggressive breast cancer histologies. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 21-32	4.4	26
259	Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. <i>Oncolimmunology</i> , 2016 , 5, e1082706	7.2	31
258	Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial 2016 ,		10
257	Abstract CT061: A phase Ib study of alpelisib (BYL719) + everolimus + exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer 2016 ,		7
256	Dendritic cell-derived exosomes for cancer therapy. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1224-32	15.9	267
255	Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 512-512	2.2	14
254	Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy □results from Paloma-3.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 524-524	2.2	8
253	SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2-advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS618-TPS618	2.2	10
252	Nuclear localization of the caspase-3-cleaved form of p73 in anoikis. <i>Oncotarget</i> , 2016 , 7, 12331-43	3.3	2
251	A Systematic Evaluation of Blood Serum and Plasma Pre-Analytics for Metabolomics Cohort Studies. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	42
250	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. <i>PLoS Medicine</i> , 2016 , 13, e1002201	22.01	214
249	Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. <i>Clinical Cancer Research</i> , 2016 , 22, 5983-5991	12.9	87
248	The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy. <i>Clinical and Translational Science</i> , 2016 , 9, 283-292	4.9	30
247	Consensus on precision medicine for metastatic cancers: a report from the MAP conference. <i>Annals of Oncology</i> , 2016 , 27, 1443-8	10.3	53

246	Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2115-24	2.2	111
245	Facilitating a culture of responsible and effective sharing of cancer genome data. <i>Nature Medicine</i> , 2016 , 22, 464-71	50.5	63
244	The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic. <i>European Journal of Cancer</i> , 2016 , 66, 131-7	7.5	22
243	Reply to D.C. Sgroi et al, T. Sanft et al, M.S. Copur et al, and M.P. Goetz et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3946-3948	2.2	3
242	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1738-1748	59.2	975
241	What to expect from high throughput genomics in metastatic breast cancers?. <i>Breast</i> , 2015 , 24 Suppl 2, S19-22	3.6	3
240	Bevacizumab: the phoenix of breast oncology?. <i>Lancet Oncology, The</i> , 2015 , 16, 600-1	21.7	8
239	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. <i>Lancet Oncology, The</i> , 2015 , 16, 816-29	21.7	213
238	Precision medicine for metastatic breast cancer--limitations and solutions. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 693-704	19.4	201
237	Targeting FGFR Signaling in Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 2684-94	12.9	301
236	Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles. <i>European Journal of Cancer</i> , 2015 , 51, 791-9	7.5	64
235	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015 , 26, 1533-46	10.3	1122
234	Impact of centralization on aCGH-based genomic profiles for precision medicine in oncology. <i>Annals of Oncology</i> , 2015 , 26, 582-8	10.3	13
233	Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHOA. <i>Breast</i> , 2015 , 24, 376-83	3.6	9
232	Ki67--no evidence for its use in node-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 296-301	19.4	47
231	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015 , 350, 972-83	33.3	267
230	Targeted therapies for ER+/HER2- metastatic breast cancer. <i>BMC Medicine</i> , 2015 , 13, 137	11.4	51
229	Natural and therapy-induced immunosurveillance in breast cancer. <i>Nature Medicine</i> , 2015 , 21, 1128-38	50.5	196

228	EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. <i>Annals of Oncology</i> , 2015 , 26, 2073-8	10.3	219
227	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. <i>Autophagy</i> , 2015 , 11, 1878-90	10.2	78
226	Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe. <i>BMC Cancer</i> , 2015 , 15, 787	4.8	5
225	TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen. <i>BMC Medical Genomics</i> , 2015 , 8, 58	3.7	29
224	Precision medicine for metastatic breast cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , e2-7	7.1	13
223	Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2015 , 373, 209-19	59.2	940
222	Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. <i>Journal of Clinical Oncology</i> , 2015 , 33, 983-91	2.2	650
221	Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. <i>Annals of Oncology</i> , 2015 , 26, 1698-704	10.3	183
220	Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 1-8	4.4	90
219	Abstract S6-01: Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 2015 ,		6
218	Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 108-108	2.2	1
217	Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 511-511	2.2	4
216	Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 512-512	2.2	6
215	Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 613-613	2.2	1
214	PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA502-LBA502	2.2	10
213	Predictive and Prognostic Value of the TauProtein in Breast Cancer. <i>Anticancer Research</i> , 2015 , 35, 5179-84		20
212	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 580-91	21.7	359
211	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. <i>Journal of Pathology</i> , 2014 , 232, 274-82	9.4	40

210	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Breast</i> , 2014 , 23, 489-502	3.6	231
209	Clinical development of mTOR inhibitors in breast cancer. <i>Breast Cancer Research</i> , 2014 , 16, 203	8.3	41
208	Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. <i>Breast Cancer Research</i> , 2014 , 16, 205	8.3	43
207	Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014 , 20, 1301-9	50.5	596
206	BOLERO-3 results: pharmacological activity or pharmacokinetic effect?--authors' reply. <i>Lancet Oncology</i> , 2014 , 15, e304-5	21.7	1
205	Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. <i>Journal of Immunology</i> , 2014 , 193, 1006-11	5.3	181
204	PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3212-20	2.2	189
203	Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. <i>BMC Medicine</i> , 2014 , 12, 132	11.4	50
202	Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1437-44	2.2	63
201	Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. <i>Cancer Treatment Reviews</i> , 2014 , 40, 1192-8	14.4	40
200	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). <i>Lancet Oncology</i> , 2014 , 15, 267-74	21.7	282
199	Chk1 as a new therapeutic target in triple-negative breast cancer. <i>Breast</i> , 2014 , 23, 250-8	3.6	37
198	Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. <i>Annals of Oncology</i> , 2014 , 25, 611-618	10.3	267
197	Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. <i>Cell Death and Differentiation</i> , 2014 , 21, 69-78	12.7	139
196	The horizon of precision medicine in breast cancer: fragmentation, alliance, or reunification?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e5-10	7.1	3
195	Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 456-68	12.9	122
194	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. <i>Annals of Oncology</i> , 2014 , 25, 2244-2251	10.3	133
193	Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. <i>Annals of Oncology</i> , 2014 , 25, 763-773	10.3	58

192	Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. <i>Current Medical Research and Opinion</i> , 2014 , 30, 1007-16	2.5	37
191	Prioritizing targets for precision cancer medicine. <i>Annals of Oncology</i> , 2014 , 25, 2295-2303	10.3	106
190	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) <i>Annals of Oncology</i> , 2014 , 25, 1871-1888	10.3	279
189	Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. <i>Genome Biology</i> , 2014 , 15, 433	18.3	53
188	Genomes in the clinic: the Gustave Roussy Cancer Center experience. <i>Current Opinion in Genetics and Development</i> , 2014 , 24, 99-106	4.9	10
187	Decision-making from multidisciplinary team meetings to the bedside: factors influencing the recruitment of breast cancer patients into clinical trials. <i>Breast</i> , 2014 , 23, 170-4	3.6	6
186	TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. <i>Molecular Oncology</i> , 2014 , 8, 508-19	7.9	49
185	Abstract CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients 2014 ,		6
184	Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11010-11010	2.2	10
183	A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8035-8035	2.2	24
182	FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS1134-TPS1134	2.2	1
181	Nonmetastatic inflammatory breast cancer: Evolution of invasive disease-free (IDFS) and overall survival (OS) over a 21-year period.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1082-1082	2.2	
180	Prognostic and predictive value of tumor infiltrating lymphocytes (TIL) in two phase III randomized adjuvant breast cancer (BC) trials.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11087-11087	2.2	1
179	Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2565-2565	2.2	
178	Genomic characterization of metastatic cisplatin-resistant samples from urothelial cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11057-11057	2.2	
177	A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. <i>Oncogene</i> , 2013 , 32, 5377-87	9.2	71
176	Gene copy number variations in breast cancer of Sub-Saharan African women. <i>Breast</i> , 2013 , 22, 295-300	3.6	7
175	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013 , 24, 2206-23	10.3	2048

174	Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2167-72	2.2	143
173	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 437-46	4.4	56
172	Prolifération des cancers du sein et biomarqueurs d'isochromosomes en pratique RPC (RPC 2013). <i>Oncologie</i> , 2013 , 15, 594-604	1	2
171	Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 28-33	12.9	147
170	Outcome in breast molecular subtypes according to nodal status and surgical procedures. <i>American Journal of Surgery</i> , 2013 , 205, 662-7	2.7	34
169	PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. <i>Lung Cancer</i> , 2013 , 80, 216-22	5.9	36
168	19q13-ERCC1 gene copy number increase in non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2013 , 14, 549-57	4.9	8
167	Quantification of residual risk of relapse in breast cancer patients optimally treated. <i>Breast</i> , 2013 , 22 Suppl 2, S92-5	3.6	15
166	Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. <i>Cancer Research</i> , 2013 , 73, 2418-27	10.1	211
165	Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. <i>Cancer Discovery</i> , 2013 , 3, 264-79	24.4	282
164	ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2013 , 368, 1101-10	59.2	284
163	Landscape and evolution of therapeutic research for breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 319-24	4.4	3
162	mTOR inhibitors in advanced breast cancer: ready for prime time?. <i>Cancer Treatment Reviews</i> , 2013 , 39, 742-52	14.4	22
161	What can be done for patients with NSCLC without druggable targets?. <i>Lancet Oncology</i> , 2013 , 14, 191-2	21.7	1
160	Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. <i>Clinical Breast Cancer</i> , 2013 , 13, 401-8	3	12
159	Personalized medicine in oncology: where have we come from and where are we going?. <i>Pharmacogenomics</i> , 2013 , 14, 931-9	2.6	36
158	AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1719-25	2.2	211
157	DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. <i>Oncologist</i> , 2013 , 18, 1063-73	5.7	64

156	Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 3693-702	12.9	236
155	Distinct tumor protein p53 mutants in breast cancer subgroups. <i>International Journal of Cancer</i> , 2013 , 132, 1227-31	7.5	74
154	ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics. <i>Cancer Research</i> , 2013 , 73, 2905-15	10.1	39
153	Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2273-81	2.2	242
152	Issues in clinical research for metastatic breast cancer. <i>Current Opinion in Oncology</i> , 2013 , 25, 625-9	4.2	7
151	Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. <i>Annals of Oncology</i> , 2013 , 24, 647-54	10.3	96
150	Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. <i>Cancer Research</i> , 2013 , 73, 2247-58	10.1	61
149	New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer. <i>Current Opinion in Oncology</i> , 2013 , 25, 587-93	4.2	10
148	ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. <i>Cell Cycle</i> , 2013 , 12, 3298-306	4.7	27
147	Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology. <i>Clinical Cancer Research</i> , 2013 , 19, 4315-25	12.9	27
146	Reproducibility of research and preclinical validation: problems and solutions. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 720-4	19.4	57
145	Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. 2013 ,		27
144	Molecular screening for cancer treatment optimization (MOSCATO 01): A prospective molecular triage trial. Interim results.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2512-2512	2.2	15
143	Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 505-505	2.2	25
142	Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIRO1).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 511-511	2.2	6
141	Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?. <i>Ecancermedicalscience</i> , 2013 , 7, 299	2.7	14
140	Dovitinib plus fulvestrant in postmenopausal endocrine resistant HER2-/ HR+ breast cancer: A phase II, randomized, placebo-controlled study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS651-TPS651	2.2	1
139	PIK3CA mutations in primary HER2-positive and triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11061-11061	2.2	

138	Molecular biology in breast cancer: should molecular classifiers be assessed by conventional tools or by gene expression arrays?. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 84 Suppl 1, e58-69	7	10
137	Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. <i>European Journal of Cancer</i> , 2012 , 48, 2293-9	7.5	21
136	Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. <i>Annals of Oncology</i> , 2012 , 23 Suppl 6, vi46-51	10.3	183
135	Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. <i>Human Pathology</i> , 2012 , 43, 1932-9	3.7	5
134	Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 84, 301-13	7	60
133	The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy. <i>Molecular Oncology</i> , 2012 , 6, 204-10	7.9	15
132	Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. <i>Science Translational Medicine</i> , 2012 , 4, 143ra99	17.5	266
131	Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 895-915	4.4	216
130	Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. <i>Annals of Oncology</i> , 2012 , 23, 2059-2064	10.3	11
129	Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. <i>Annals of Oncology</i> , 2012 , 23, 2245-2252	10.3	53
128	DNA repair capacity in circulating lymphocytes and influence on platinum effect in tumor cells. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1567-8; author reply 1568-9	2.2	2
127	Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups. <i>Clinical Cancer Research</i> , 2012 , 18, 1555-60	12.9	25
126	Triple-negative breast cancer: are we making headway at least?. <i>Therapeutic Advances in Medical Oncology</i> , 2012 , 4, 195-210	5.4	60
125	A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. <i>British Journal of Cancer</i> , 2012 , 106, 1107-16	8.7	35
124	Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2012 , 23, 2046-2052	10.3	25
123	mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. <i>Annals of Oncology</i> , 2012 , 23, 2526-2535	10.3	37
122	Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1996-2004	2.2	167
121	Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. <i>Annals of Oncology</i> , 2012 , 23, 2997-3006	10.3	189

120	Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?. <i>Breast Care</i> , 2012 , 7, 267-72	2.4	11
119	Conference Scene: Advances in breast cancer translational research. <i>Breast Cancer Management</i> , 2012 , 1, 197-199	0.7	
118	Interpathologists discrepancies in Ki67 assessment in the PACS01 trial: An independent prognosis factor.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 543-543	2.2	1
117	Implications of personalized medicine--perspective from a cancer center. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 177-83	19.4	44
116	Biomarker studies: a call for a comprehensive biomarker study registry. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 171-6	19.4	86
115	Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. <i>European Journal of Cancer</i> , 2011 , 47, 2249-55	7.5	36
114	Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. <i>Breast Cancer Research</i> , 2011 , 13, R109	8.3	18
113	Tumor genotyping for breast cancer: at the front door. <i>Personalized Medicine</i> , 2011 , 8, 383-385	2.2	
112	TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. <i>Cancer Research</i> , 2011 , 71, 1607-14	10.1	87
111	Le point de vue du clinicien : ciblage des kinases en pathologie mammaire. <i>Annales De Pathologie</i> , 2011 , 31, S39	0.3	
110	Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 78, 195-205	7	21
109	Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 264-72	9.7	175
108	Biology-driven phase II trials: what is the optimal model for molecular selection?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1236-8	2.2	56
107	Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. <i>Clinical Cancer Research</i> , 2011 , 17, 2591-601	12.9	39
106	A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. <i>British Journal of Cancer</i> , 2011 , 105, 847-53	8.7	322
105	Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. <i>Clinical Cancer Research</i> , 2011 , 17, 5562-72	12.9	50
104	ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. <i>Annals of Oncology</i> , 2011 , 22, 575-581	10.3	11
103	Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening. <i>British Journal of Cancer</i> , 2010 , 102, 462-8	8.7	30

102	Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 367-80	19.4	84
101	Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials. <i>Oncologist</i> , 2010 , 15, 476-83	5.7	6
100	Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. <i>Cancer Research</i> , 2010 , 70, 490-500	10.1	87
99	Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?. <i>Annals of Oncology</i> , 2010 , 21 Suppl 7, vii30-5	10.3	73
98	Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5110-5	2.2	176
97	Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. <i>Cancer Research</i> , 2010 , 70, 9538-43	10.1	24
96	Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4316-23	2.2	163
95	First-generation genomic tests for breast cancer treatment. <i>Lancet Oncology, The</i> , 2010 , 11, 6-7	21.7	10
94	Genomic index of sensitivity to endocrine therapy for breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4111-9	2.2	203
93	Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. <i>Genome Medicine</i> , 2010 , 2, 53	14.4	36
92	Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. <i>Oncologist</i> , 2010 , 15, 246-52	5.7	40
91	DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 341-5	2.7	31
90	Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. <i>Current Opinion in Oncology</i> , 2010 , 22, 547-51	4.2	42
89	Rapport 2009 sur l'état des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1, Oncotype DX et MammaPrint dans la prise en charge du cancer du sein. <i>Oncologie</i> , 2010 , 12, 158-163	1	2
88	Traitements médicaux guidés par la biologie en pathologie mammaire. <i>Oncologie</i> , 2010 , 12, 274-277	1	1
87	Breast Cancer Classification to Select Patients for Cancer Treatment. <i>Current Breast Cancer Reports</i> , 2010 , 2, 152-158	0.8	
86	Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 747-55	4.4	40
85	Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging. <i>Clinical Breast Cancer</i> , 2010 , 10, 113-8	3	13

84	Expression of chemokine receptor CCR6 as a molecular determinant of adrenal metastatic relapse in patients with primary lung cancer. <i>Clinical Lung Cancer</i> , 2010 , 11, 187-91	4.9	23
83	A nomogram to predict for malignant diagnosis of BI-RADS Category 4 breast lesions. <i>Journal of Surgical Oncology</i> , 2010 , 102, 220-4	2.8	8
82	Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. <i>Proteomics</i> , 2010 , 10, 3525-32	4.8	15
81	CXCR4 expression in early breast cancer and risk of distant recurrence. <i>Oncologist</i> , 2009 , 14, 1182-8	5.7	52
80	Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4287-92	2.2	68
79	Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2809-15	2.2	178
78	Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. <i>Clinical Cancer Research</i> , 2009 , 15, 441-51	12.9	265
77	P53 family: at the crossroads in cancer therapy. <i>Current Medicinal Chemistry</i> , 2009 , 16, 4328-44	4.3	29
76	Fine-needle aspiration for nucleic acid-based molecular analyses in breast cancer. <i>Cancer Cytopathology</i> , 2009 , 117, 32-9	3.9	12
75	Evaluating beauty care provided by the hospital to women suffering from breast cancer: qualitative aspects. <i>Supportive Care in Cancer</i> , 2009 , 17, 839-45	3.9	16
74	Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. <i>Nature Medicine</i> , 2009 , 15, 1170-8	50.5	1284
73	Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. <i>Lancet Oncology</i> , 2009 , 10, 381-90	21.7	50
72	Neoadjuvant chemotherapy for breast cancers: current recommendations and future directions. <i>European Journal of Cancer</i> , 2009 , 45 Suppl 1, 368-70	7.5	3
71	Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. <i>PLoS ONE</i> , 2009 , 4, e4942	3.7	286
70	Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. <i>British Journal of Cancer</i> , 2008 , 99, 68-71	8.7	28
69	Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses. <i>BMC Bioinformatics</i> , 2008 , 9, 149	3.6	14
68	Evaluation of biological pathways involved in chemotherapy response in breast cancer. <i>Breast Cancer Research</i> , 2008 , 10, R37	8.3	50
67	Gene expression predictors in breast cancer: current status, limitations and perspectives. <i>European Journal of Cancer</i> , 2008 , 44, 2714-20	7.5	45

66	Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1275-81	2.2	1917
65	Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. <i>Annals of Oncology</i> , 2008 , 19, 1402-1406	10.3	14
64	p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. <i>Annals of Oncology</i> , 2008 , 19, 1261-1265	10.3	49
63	Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4679-83	2.2	26
62	Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. <i>Annals of Oncology</i> , 2008 , 19, 315-20	10.3	28
61	Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. <i>Annals of Oncology</i> , 2008 , 19, 1875-81	10.3	39
60	The anticancer immune response: indispensable for therapeutic success?. <i>Journal of Clinical Investigation</i> , 2008 , 118, 1991-2001	15.9	450
59	Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2636-43	2.2	44
58	HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008 , 108, 183-90	4.4	78
57	Lésions bénignes du sein et risque de transformation maligne : le point de vue de l'oncologue aujourd'hui. <i>Imagerie De La Femme</i> , 2007 , 17, 119-123	0.1	
56	Gene-Expression Biomarkers as Predictors of Recurrence and Treatment-Related Outcomes in Breast Cancer. <i>Breast Diseases</i> , 2007 , 18, 133-135		1
55	D3-03: IALT-Bio: a challenging research to improve adjuvant chemotherapy of completely resected NSCLC. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S397-S398	8.9	6
54	PD2-3-4: Prognostic and predictive value of apoptosis related factors Fas, FasL and survivin in non small cell lung carcinoma patients enrolled in the IALT Trial. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S444-S445	8.9	5
53	Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. <i>Cancer</i> , 2007 , 109, 496-501	6.4	37
52	Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. <i>Nature Medicine</i> , 2007 , 13, 1050-9	50.5	2207
51	The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. <i>Immunological Reviews</i> , 2007 , 220, 47-59	11.3	431
50	Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2650-5	2.2	215
49	Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer. <i>Annals of Oncology</i> , 2007 , 18, 1793-8	10.3	27

48	Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. <i>Annals of Oncology</i> , 2007 , 18, 1477-83	10.3	66
47	Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. <i>Annals of Oncology</i> , 2007 , 18, 1285-6	10.3	63
46	Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. <i>Clinical Cancer Research</i> , 2007 , 13, 3892-8	12.9	63
45	What can breast cancer molecular sub-classification add to conventional diagnostic tools?. <i>Annals of Oncology</i> , 2007 , 18 Suppl 9, ix33-6	10.3	4
44	Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 2061-7	12.9	102
43	Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. <i>Annals of Oncology</i> , 2007 , 18, 874-80	10.3	56
42	Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2735-40	2.2	85
41	Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. <i>Lancet Oncology</i> , 2007 , 8, 203-11	21.7	157
40	DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2006 , 1766, 197-204	11.2	12
39	Dendritic cell derived-exosomes: biology and clinical implementations. <i>Journal of Leukocyte Biology</i> , 2006 , 80, 471-8	6.5	103
38	Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 621-32		100
37	Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. <i>Annals of Oncology</i> , 2006 , 17, 945-51	10.3	149
36	DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. <i>New England Journal of Medicine</i> , 2006 , 355, 983-91	59.2	1424
35	Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. <i>Pharmaceutical Research</i> , 2006 , 23, 1951-8	4.5	10
34	Hétérogénéité moléculaire des cancers du sein: quelles implications pour la sélection des patientes en vue d'une chimiothérapie adjuvante?. <i>Oncologie</i> , 2006 , 8, 235-242	1	
33	Management of Extensive Small-Cell Lung Cancer 2006 , 371-376		
32	The potential of exosomes in immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2005 , 5, 737-47	5.4	40
31	The potential of exosomes in immunotherapy of cancer. <i>Blood Cells, Molecules, and Diseases</i> , 2005 , 35, 111-5	2.1	36

30	Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC. <i>European Journal of Cancer</i> , 2005 , 41, 2112-9	7.5	24
29	Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. <i>Journal of Translational Medicine</i> , 2005 , 3, 10	8.5	769
28	Chemoprevention of lung cancer. <i>Recent Results in Cancer Research</i> , 2005 , 166, 145-65	1.5	2
27	Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. <i>Annals of Oncology</i> , 2005 , 16, 1846-7	10.3	62
26	Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8331-9	2.2	218
25	Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2996-3000	2.2	27
24	Breast cancer with synchronous metastases: trends in survival during a 14-year period. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3302-8	2.2	339
23	Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. <i>Annals of Oncology</i> , 2004 , 15, 613-7	10.3	178
22	Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. <i>Journal of Immunology</i> , 2004 , 172, 2137-46	5.3	204
21	Her2-neu: a target in lung cancer?. <i>Annals of Oncology</i> , 2004 , 15, 3-4	10.3	9
20	Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. <i>Journal of Immunology</i> , 2004 , 172, 2126-36	5.3	357
19	Risk factors for brain relapse in patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2004 , 15, 1640-4	10.3	116
18	Exosomes for cancer immunotherapy. <i>Annals of Oncology</i> , 2004 , 15 Suppl 4, iv141-4	10.3	62
17	Exosome-based immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2004 , 53, 234-9	7.4	91
16	Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. <i>Cancer</i> , 2004 , 101, 918-25	6.4	52
15	Exosomes for Immunotherapy of Cancer 2004 , 331-340		1
14	A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. <i>Lung Cancer</i> , 2003 , 39, 55-61	5.9	173
13	Exosomes for immunotherapy of cancer. <i>Advances in Experimental Medicine and Biology</i> , 2003 , 532, 215-216		40

12	Malignant effusions and immunogenic tumour-derived exosomes. <i>Lancet, The</i> , 2002 , 360, 295-305	40	722
11	Magnetic minerals as indicators of major environmental change in holocene black sea sediments: preliminary results. <i>Physics and Chemistry of the Earth</i> , 2002 , 27, 1363-1370	3	17
10	Tumor-derived exosomes: a new source of tumor rejection antigens. <i>Vaccine</i> , 2002 , 20 Suppl 4, A28-31	4.1	151
9	Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy. <i>Cancer</i> , 2001 , 91, 2394-2400	6.4	105
8	Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors. <i>British Journal of Cancer</i> , 2001 , 84, 903-9	8.7	50
7	Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2001 , 122, 796-802	1.5	107
6	Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. <i>Journal of Immunology</i> , 2001 , 167, 1795-802	5.3	64
5	Persistence of viable tumor cells after radiation and chemotherapy for stage IIIB non-small cell lung cancer: an early marker of treatment failure. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2001 , 121, 403	1.5	3
4	Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2981-9	2.2	407
3	Peritoneal carcinomatosis in germ-cell tumor: relations with retroperitoneal lymph node dissection. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000 , 23, 460-2	2.7	4
2	The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. <i>European Journal of Cancer</i> , 2000 , 36, 1389-94	7.5	171
1	Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. <i>Journal of Clinical Oncology</i> , 1998 , 16, 3736-43	2.2	100